Evidence map›Paper›PMID 25963795›Full record

ArticleJournal of cancer research and clinical oncology2015

Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.

Masahiro Morise, Tomoyuki Hishida, Akiko Takahashi, Junji Yoshida, Yuichiro Ohe, Kanji Nagai, Genichiro Ishii

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.International journal of molecular sciences · 2022
    Review
  3. Pulmonary Large Cell Neuroendocrine Carcinoma.Pathology oncology research : POR · 2022
    Review
  4. [Advances in Molecular Biomarker for Pulmonary Large Cell Neuroendocrine Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Cancer stem cells in small cell lung cancer.Translational lung cancer research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masahiro MoriseDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tomoyuki HishidaDepartment of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. thishida@east.ncc.go.jp.
Akiko TakahashiDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Junji YoshidaDepartment of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kanji NagaiDepartment of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Genichiro IshiiPathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
National Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the clinicopathological significance of cancer stem-like cell (CSLC) markers in high-grade neuroendocrine carcinoma (HGNEC) of the lung, including small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC).

methodsWe retrospectively studied patients who underwent surgical resection of SCLC (n = 60) and LCNEC (n = 45) to analyze their clinicopathological profiles and the immunohistochemical expression of putative CSLC markers (Caveolin, Notch, CD44, CD166, SOX2, ALDH1, and Musashi1). Staining scores for these markers in tumor cells were calculated by multiplying the percentage of positive tumor cells per lesion by the staining intensity level (0, 1, and 2); a score of ≥ 10 represented positive expression.

resultsThere was a difference between SCLC and LCNEC with respect to both SOX2 (55 vs. 27 %, p = 0.003) and CD166 (27 vs. 47 %, p = 0.034) expression. ALDH1 expression was equally observed in SCLC and LCNEC (67 vs. 73 %, p = 0.46), and patients with ALDH1-positive HGNEC had significantly worse recurrence-free survival (RFS) and overall survival (OS) rates than those with ALDH1-negative HGNEC (5-year RFS: 39 vs. 67 %, p = 0.009; 5-year OS: 50 vs. 79 %, p = 0.021). A multivariate analysis revealed that positive ALDH1 expression was an independent unfavorable prognostic factor with respect to both RFS and OS.

conclusionsThe differences in the expression profiles of CSLC markers might reflect morphological differences between SCLC and LCNEC. Positive ALDH1 expression in lung HGNEC was associated with an unfavorable patient prognosis, which suggested that ALDH1-positive tumor cells might be future therapeutic targets for the treatment of lung HGNEC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Large CellCarcinoma, NeuroendocrineFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessBiomarkers, TumorAldehyde dehydrogenase 1 (ALDH1)Cancer stem-like cellsHigh-grade neuroendocrine carcinomaLarge cell neuroendocrine carcinomaSmall cell lung carcinoma

Identifiers

PMID25963795
PMCPMC11823834
OpenAlexW1916702960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.